NASDAQ:GNCAQ Genocea Biosciences (GNCAQ) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 05/22/2026 10:59 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Genocea Biosciences Stock (NASDAQ:GNCAQ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genocea Biosciences alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0001Volume156 shsAverage Volume1,863 shsMarket Capitalization$5.30 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genocea Biosciences is a clinical-stage biotechnology company focused on the discovery and development of T-cell vaccines for infectious diseases and cancer. The company leverages a deep understanding of cellular immunity to identify and prioritize antigens that stimulate robust T-cell responses, addressing areas of high unmet medical need. At the core of Genocea’s research platform is ATLAS, a proprietary technology that profiles patient T-cell responses against a broad array of potential antigens. By mapping how immune cells recognize disease-relevant targets, ATLAS enables the selection of candidates with the greatest likelihood of efficacy and supports both therapeutic and prophylactic vaccine design. Founded in 2011 as a spin-out from Harvard Medical School, Genocea has advanced its lead program, GEN-003, through Phase II clinical trials for recurrent genital herpes, demonstrating favorable safety and immunogenicity profiles. The company continues to apply lessons learned from this work to additional infectious disease and oncology targets, moving promising candidates toward human studies. Headquartered in Cambridge, Massachusetts, Genocea brings together a leadership team with extensive experience in immunology, clinical development and biopharmaceutical strategy. The company collaborates with academic institutions and industry partners to broaden its pipeline and expand the global reach of its vaccine candidates.AI Generated. May Contain Errors. Read More Receive GNCAQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNCAQ Stock News HeadlinesMicrobix Biosystems Inc. (MBXBF)July 25, 2024 | finance.yahoo.comGenocea Bio (GNCAQ) Earnings Dates & ReportsAugust 19, 2023 | investing.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)Genocea Biosciences Inc (GNCAQ)August 11, 2023 | uk.investing.comGNCAQ - Genocea Biosciences, Inc.June 1, 2023 | ca.finance.yahoo.comSee More Headlines GNCAQ Stock Analysis - Frequently Asked Questions How have GNCAQ shares performed this year? Genocea Biosciences' stock was trading at $0.0001 at the beginning of the year. Since then, GNCAQ stock has increased by 0.0% and is now trading at $0.0001. How do I buy shares of Genocea Biosciences? Shares of GNCAQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNCAQ CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,020,000Free FloatN/AMarket Cap$5.30 thousand OptionableNot Optionable Beta2.53 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:GNCAQ) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
